Research on the treatment of rifampin-susceptible tuberculosis-Time for a new approach.

IF 15.8 1区医学 Q1 Medicine

PLoS Medicine Pub Date : 2024-07-25 eCollection Date: 2024-07-01 DOI:10.1371/journal.pmed.1004438

William Burman, Oxana Rucsineanu, C Robert Horsburgh, James Johnston, Susan E Dorman, Dick Menzies

引用次数: 0

Abstract

In the Perspective, William Burman and colleagues advocate improving the safety and acceptability of treatment, rather than treatment-shortening, of rifampin-susceptible tuberculosis.

查看原文本刊更多论文

利福平敏感型肺结核治疗研究--是时候采用新方法了。

威廉-伯曼及其同事在《视角》中主张提高利福平易感结核病治疗的安全性和可接受性，而不是缩短治疗时间。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

PLoS Medicine MEDICINE, GENERAL & INTERNAL-

CiteScore

17.60

自引率

0.60%

发文量

227

审稿时长

4-8 weeks

期刊介绍： PLOS Medicine is a prominent platform for discussing and researching global health challenges. The journal covers a wide range of topics, including biomedical, environmental, social, and political factors affecting health. It prioritizes articles that contribute to clinical practice, health policy, or a better understanding of pathophysiology, ultimately aiming to improve health outcomes across different settings. The journal is unwavering in its commitment to uphold the highest ethical standards in medical publishing. This includes actively managing and disclosing any conflicts of interest related to reporting, reviewing, and publishing. PLOS Medicine promotes transparency in the entire review and publication process. The journal also encourages data sharing and encourages the reuse of published work. Additionally, authors retain copyright for their work, and the publication is made accessible through Open Access with no restrictions on availability and dissemination. PLOS Medicine takes measures to avoid conflicts of interest associated with advertising drugs and medical devices or engaging in the exclusive sale of reprints.